Jun 05,2023

Aster Insights announces that The University of Kansas Cancer Center will join the Oncology Research Information Network (ORIEN)

Aster Insights (formerly known as M2GEN), the leading provider of technology-enabled data and analytics solutions for oncology discovery, today announced The University of Kansas Cancer Center will join its Oncology Research Information Exchange Network (ORIEN). The KU Cancer Center will be the latest NCI-designated cancer center to join ORIEN, which is comprised of 18 cancer centers across the U.S. dedicated to collaborative research to accelerate cancer discovery and development. Launched in 2014, ORIEN is the largest and longest-running academic cancer research consortium of its kind in the United States. ORIEN members participate in the Total Cancer Care (TCC) protocol, the largest lifetime-consented patient research program in oncology, utilizing deep clinical and genomic data to best support patient care, research, and discovery.

COLLABORATION PARTNERSHIP

#institution

#rwd

View Analyst & Ambassador Comments
Go to original news
May 17,2023

Flatiron adds service with 'data empathy' for oncology trials

Flatiron Health debuted its latest offering of its real-world evidence (RWE) platform to include data and end-to-end services focused on growing needs in the arena of oncology clinical trials. The additions by Flatiron provide a one-stop-shop for oncology real-world data by giving customers more flexibility in the way they engage with the platform to deliver oncology evidence solutions tailored to their particular needs, the company said in a May 15 press release.

PRODUCT

#rwe

#rwd

View Analyst & Ambassador Comments
Go to original news
Apr 27,2023

Twist Bioscience and Aster Insights (previously M2GEN) Partner on Launch of Next Generation Oncology Panel for Cancer Research

Twist Bioscience Corporation (NASDAQ: TWST), a company enabling customers to succeed through its offering of high-quality synthetic DNA using its silicon platform, and Aster Insights, a bioinformatics company with the most advanced, direct-patient, lifetime-consented clinicogenomics data to accelerate oncology discovery research, today announced the availability of the AsterExome panel, which can simultaneously enable whole exome sequencing (WES) with additional coverage for target regions known to contain 620 genes associated with cancer. The AsterExome panel will be integrated into Aster Insights’ AVATAR program, which can enable informatics-based analysis of paired tumor and germline DNA and RNA sequencing data from patients consented via the Total Cancer Care® (TCC) protocol. Aster Insight’s real-world AVATAR data set comes from its Oncology Research Information Exchange Network® (ORIEN) partners

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Apr 25,2023

PathAI and ConcertAI Partner to Create First-in-class Histopathology and Curated Clinical Real-World Data Product

PathAI, a global leader in AI-powered pathology, and ConcertAI, a leader in AI software-as-a-service (SaaS) technology and real-world evidence (RWE) solutions for life sciences and healthcare, today announced a strategic partnership to launch a first-in-class quantitative histopathology and curated clinical real-world data (RWD) solution combining PathAI’s PathExplore™ tumor microenvironment panel with ConcertAI’s Patient360™ and RWD360™ products. Utilizing real world H&E-stained samples from PathAI’s pathology laboratory, PathExplore extracts quantitative measures of the tumor microenvironment, known as human interpretable features (HIFs), from whole slide images. These data are linked to Patient360’s reference-standard abstracted clinical EMR, medical claims, and Social Determinants of Health data, allowing direct insights into current standards of care and treatment dynamics. ConcertAI and PathAI will jointly offer these combined solutions to biopharma customers, including translational research and real-world data teams. The initial solutions focus on bladder cancer, colorectal cancer, prostate cancer, and melanoma.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Apr 20,2023

Real-world data control arm provides new look into effectiveness of lymphoma therapies

Real-world data can uncover vital efficacy info for new treatments. In the development of an external control arm for lisocabtagene maraleucel in patients with R/R large B-cell lymphoma, Bristol Myers Squibb used COTA’s RWD. Using real-world data from COTA and other sources, the team developed an external control arm to provide additional context around the efficacy of lisocabtagene maraleucel (liso-cel) compared with conventional (noncellular) therapies in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL).

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Apr 03,2023

Tempus Announces Second Sequencing Collaboration with Lilly to Expand Patient Access to Genomic Testing

Tempus, a leader in artificial intelligence and precision medicine, today announced a new collaboration sponsored by Eli Lilly and Company designed to expand access to genomic testing for eligible patients who have advanced or metastatic medullary thyroid cancer or advanced or metastatic non-medullary thyroid cancer. This collaboration offers Tempus’ molecular profiling offerings at no cost while simultaneously working with physicians to support them in providing data-driven treatment to their patients with the use of broad-panel genomic testing. This collaboration builds upon the initial partnership with Lilly announced in June 2022 focused on providing broader access to genomic testing for patients with advanced/metastatic non-small cell lung cancer.

COLLABORATION PARTNERSHIP

#product & service

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Apr 02,2023

Absci Partners with M2GEN to Accelerate Drug Creation for Oncology

Absci Corporation (Nasdaq: ABSI), a generative AI drug creation company, and M2GEN, an oncology bioinformatics company with the most advanced lifetime-consented clinicogenomics data to accelerate discovery research, today announced a partnership to create new cancer medicines and bring them to market at unprecedented speed. Absci’s generative AI drug creation platform will tap into M2GEN’s clinical and molecular data set, ORIEN AVATAR® (AVATAR), to accelerate the creation of therapeutics for a range of malignancies and patient profiles, bringing AI drug creation to the fight against cancer. This partnership brings together AI drug creation technology and oncology bioinformatics to potentially reduce the time and cost to create better cancer treatments.

COLLABORATION PARTNERSHIP

#r&d

#ai/software

#rwd

View Analyst & Ambassador Comments
Go to original news
Mar 31,2023

NCCN: Enabling real-world cancer research with real-world data from COTA

Some of COTA Healthcare's latest work has been accepted for presentation at the National Comprehensive Cancer Network (NCCN) 2023 Annual Conference. NCCN is the organization responsible for stewarding cancer care guidelines and standards of care. Using novel real-world data (RWD), such as EHR data, claims, and registry information, researchers and clinicians can uncover hidden patterns in cancer care and treatment models.

#rwd

#rwe

View Analyst & Ambassador Comments
Go to original news
Mar 08,2023

In Move to Power Precision Oncology for Patients, COTA and Genomic Testing Cooperative Form New Data Partnership

COTA, Inc., an oncology real-world data and analytics company, today announced a new partnership with Genomic Testing Cooperative (GTC), a molecular testing company. The two companies are joining forces to integrate COTA’s deep clinical oncology real-world data with GTC’s comprehensive genomics testing data. This strategic and oncology-specific partnership, grounded in deep comprehensive clinical data, will support more precise, personalized cancer research particularly across early discovery and translational epidemiology functions.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Jan 24,2023

Aetion Collaborates With FDA to Explore Oncology RWD for Regulatory Science Research

Aetion, the global leader in real-world evidence (RWE) technology and analytics, today announced a five-year research collaboration with the U.S. Food and Drug Administration (FDA) Oncology Center of Excellence (OCE) to advance research using novel oncology real-world data (RWD) sources through platform analytics on the Aetion Evidence Platform® (AEP). Through this research collaboration, Aetion and the FDA will use the AEP to identify and analyze fit-for-purpose RWD sources to address key research questions that are relevant to prevention, clinical care, diagnostics, and treatment, in oncology. The research objectives include assessing real-world endpoints, evaluation of causal inference methods, and measuring and understanding health disparities to advance health equity.

COLLABORATION PARTNERSHIP

#data & technology

#rwd

View Analyst & Ambassador Comments
Go to original news
Subscribe to RWD